Cargando…
1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities
BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) that are resistant only to one carbapenem have been reported, but the frequency of discordance between ertapenem and imipenem/meropenem is not known for Enterobacter species. We investigated the occurrence of discordant carbapenem susceptibil...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255083/ http://dx.doi.org/10.1093/ofid/ofy210.888 |
_version_ | 1783373875314163712 |
---|---|
author | Chou, Andrew Rossi, Vittoria Sucgang, Richard Hamill, Richard Zechiedrich, Lynn Trautner, Barbara W |
author_facet | Chou, Andrew Rossi, Vittoria Sucgang, Richard Hamill, Richard Zechiedrich, Lynn Trautner, Barbara W |
author_sort | Chou, Andrew |
collection | PubMed |
description | BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) that are resistant only to one carbapenem have been reported, but the frequency of discordance between ertapenem and imipenem/meropenem is not known for Enterobacter species. We investigated the occurrence of discordant carbapenem susceptibilities in Enterobacter species bacteremia and the potential association with increased mortality. METHODS: We examined all cases of Enterobacter species bacteremia from January 2012 to December 2016 at the Michael E. DeBakey VA Medical Center in Houston, Texas, USA. Clinical and microbiological data were independently extracted by two investigators. Antibiotic susceptibility testing results were interpreted according to current CLSI breakpoints. RESULTS: We found 14/67 (20.9%) isolates had discordance between ertapenem and imipenem susceptibilities. Eight isolates were ertapenem susceptible/imipenem nonsusceptible and six isolates were ertapenem nonsusceptible/imipenem susceptible (table). Bacteremia cleared in 94.5% (52/55) of all patients who had follow-up cultures, including infection by all (13/13) isolates with discordant carbapenem susceptibilities tested. Thirty-day mortality was statistically higher in infection by isolates with discordant carbapenem susceptibilities than by isolates that were susceptible to all tested carbapenems (10% vs. 36%; P = 0.03, Fisher’s exact test). In-hospital mortality was also higher in the discordant cohort as well (12% vs. 36%; P = 0.04, Fisher’s exact test). Acute severity of illness at bacteremia onset did not differ between the groups (median Pitt bacteremia score 2 vs. 3; P = 0.11, Wilcoxon rank-sum test). CONCLUSION: Bacteremia by Enterobacter species with discordant ertapenem and imipenem/meropenem susceptibilities is a relevant clinical issue, occurring in 20.9% of Enterobacter species bacteremias at our institution, and the discordance is associated with increased mortality. Whether such species can be safely treated with one carbapenem but not another is worth further investigation. MIC: minimum inhibitory concentration; S: susceptible; I: intermediate; R: resistant; DISCLOSURES: B. W. Trautner, Paratek: Consultant, Consulting fee. Zambon: Consultant, Consulting fee and Research grant. |
format | Online Article Text |
id | pubmed-6255083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62550832018-11-28 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities Chou, Andrew Rossi, Vittoria Sucgang, Richard Hamill, Richard Zechiedrich, Lynn Trautner, Barbara W Open Forum Infect Dis Abstracts BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) that are resistant only to one carbapenem have been reported, but the frequency of discordance between ertapenem and imipenem/meropenem is not known for Enterobacter species. We investigated the occurrence of discordant carbapenem susceptibilities in Enterobacter species bacteremia and the potential association with increased mortality. METHODS: We examined all cases of Enterobacter species bacteremia from January 2012 to December 2016 at the Michael E. DeBakey VA Medical Center in Houston, Texas, USA. Clinical and microbiological data were independently extracted by two investigators. Antibiotic susceptibility testing results were interpreted according to current CLSI breakpoints. RESULTS: We found 14/67 (20.9%) isolates had discordance between ertapenem and imipenem susceptibilities. Eight isolates were ertapenem susceptible/imipenem nonsusceptible and six isolates were ertapenem nonsusceptible/imipenem susceptible (table). Bacteremia cleared in 94.5% (52/55) of all patients who had follow-up cultures, including infection by all (13/13) isolates with discordant carbapenem susceptibilities tested. Thirty-day mortality was statistically higher in infection by isolates with discordant carbapenem susceptibilities than by isolates that were susceptible to all tested carbapenems (10% vs. 36%; P = 0.03, Fisher’s exact test). In-hospital mortality was also higher in the discordant cohort as well (12% vs. 36%; P = 0.04, Fisher’s exact test). Acute severity of illness at bacteremia onset did not differ between the groups (median Pitt bacteremia score 2 vs. 3; P = 0.11, Wilcoxon rank-sum test). CONCLUSION: Bacteremia by Enterobacter species with discordant ertapenem and imipenem/meropenem susceptibilities is a relevant clinical issue, occurring in 20.9% of Enterobacter species bacteremias at our institution, and the discordance is associated with increased mortality. Whether such species can be safely treated with one carbapenem but not another is worth further investigation. MIC: minimum inhibitory concentration; S: susceptible; I: intermediate; R: resistant; DISCLOSURES: B. W. Trautner, Paratek: Consultant, Consulting fee. Zambon: Consultant, Consulting fee and Research grant. Oxford University Press 2018-11-26 /pmc/articles/PMC6255083/ http://dx.doi.org/10.1093/ofid/ofy210.888 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Chou, Andrew Rossi, Vittoria Sucgang, Richard Hamill, Richard Zechiedrich, Lynn Trautner, Barbara W 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities |
title | 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities |
title_full | 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities |
title_fullStr | 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities |
title_full_unstemmed | 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities |
title_short | 1051. Increased Mortality in Bacteremia by Enterobacter Species With Discordant Imipenem and Ertapenem Susceptibilities |
title_sort | 1051. increased mortality in bacteremia by enterobacter species with discordant imipenem and ertapenem susceptibilities |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255083/ http://dx.doi.org/10.1093/ofid/ofy210.888 |
work_keys_str_mv | AT chouandrew 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities AT rossivittoria 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities AT sucgangrichard 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities AT hamillrichard 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities AT zechiedrichlynn 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities AT trautnerbarbaraw 1051increasedmortalityinbacteremiabyenterobacterspecieswithdiscordantimipenemandertapenemsusceptibilities |